---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-064117"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-10-01T12:34:15+00:00"
generated_at: "2026-10-12T14:17:39.525603+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.62
calibrated_materiality_score: 0.62
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology names Aziz Sawaf CFO effective October 5, 2026

## Summary
- Vir named Aziz Sawaf EVP and CFO effective Oct. 5, 2026; Brent Sabatini ceases as interim principal financial officer, staying as SVP/Chief Accounting Officer.
- Sawaf, Theravance CFO since 2023 and ex-Gilead finance, gets $520,000 base salary, 45% target bonus, $150,000 sign-on.
- Equity grant around Nov. 15, 2026 includes options for 150,000 shares and 75,000 RSUs, each vesting over four years; option vests 25% on first anniversary then monthly.
- Under Vir's severance plan, a covered termination during the 12-month post-change-in-control period gives 12 months' salary plus target bonus, health benefits, and full equity acceleration.
- Outside that period, severance is nine months' salary plus pro-rated target bonus and up to nine months of health benefits.

## SEC filing metadata
- accession: 0001628280-26-064117
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-10-01T12:34:15+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.62
- calibrated_materiality_score: 0.62
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026064117/0001628280-26-064117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026064117/vir-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-064117
- JSON: https://secwatch.observer/filing/0001628280-26-064117.json
- Plain text: https://secwatch.observer/filing/0001628280-26-064117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.